PD-1 anticorps (FITC)

N° du produit ABIN2661634

Détail du produit anti-PD-1 anticorps (FITC)

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-1 est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Réactivité croisée: Chimpanzé, Marmoset, Macaque rhésus, Squirrel Monkey (Saimiri spec.), Cynomolgus

Purification: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

Clone: EH12-2H7

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur PD-1

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Autre désignation: CD279 (PDCD1 Produits)

Synonymes: anticorps CD279, anticorps PD-1, anticorps PD1, anticorps SLEB2, anticorps hPD-1, anticorps hPD-l, anticorps Ly101, anticorps Pdc1, anticorps programmed cell death 1, anticorps PDCD1, anticorps Pdcd1

Sujet: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Pathways: Cancer Immune Checkpoints